Curaleaf reports Q1 2026 revenue of $324M with 6% growth and $70M net income amid strategic expansion.

Curaleaf Holdings reported first quarter 2026 revenue of $324 million, a 6% increase year-over-year, driven by 2% domestic and 35% international growth. The company achieved a gross profit margin of 49% and net income of $70 million, reflecting strong operational performance despite some margin pressure. Curaleaf expanded its retail footprint in key U.S. states and completed the full acquisition of its German subsidiary, Four 20 Pharma. The company also filed for DEA registration, positioning itself for growth following recent regulatory changes in medical cannabis. Curaleaf's strategic investments and new product launches support its outlook for continued industry leadership.